108 New Drug Facilities in Nigeria. Most Have Never Been Inspected.

Nigeria's National Agency for Food and Drug Administration and Control published results from its 5+5 Policy in March 2026 showing 108 new pharmaceutical manufacturing facility layouts approved, 20 facilities completed, and 88 more actively under construction. Import dependency for medicines covered under the policy has dropped from approximately 70 percent to roughly 50 percent. Of those 108 facilities, 58 percent are being built by manufacturers with no prior pharmaceutical production history, entering a supply chain where WHO prequalification assessments will eventually apply the international GMP scrutiny that local approval processes are not designed to replicate.

These numbers represent a genuine policy success. NAFDAC processed 191 applications under the 5+5 program and approved 185 of them, a 97 percent approval rate that signals a regulator actively enabling manufacturing growth rather than gatekeeping it. Two Nigerian manufacturers have achieved WHO prequalification under the policy's tenure: Swiss Pharma for paediatric zinc and sulfadoxine/pyrimethamine products, and Afrimedical for auto-disable syringes. Both milestones require sustained investment in quality infrastructure that goes well beyond building construction. They reflect quality systems built for international scrutiny, not just for local intake review.

The challenge that follows from this expansion is a quality one, not a policy one. NAFDAC's layout approval process evaluates facility design, workflow appropriateness, and physical infrastructure. It does not evaluate the quality system that will operate inside the facility once construction completes. That system, the SOPs, the deviation management process, the CAPA program, the laboratory controls, the environmental monitoring plan, the data integrity practices, is what a WHO, FDA, or EMA inspector will actually examine when a manufacturer seeks international market access. Approval of the building is not approval of what happens inside it.

New manufacturers face a calibration gap that experienced sites have already paid for through prior inspection cycles. An experienced quality team writes SOPs that answer the questions an investigator will ask. A new quality team writes SOPs that describe the intended process. Both produce documentation. Only one produces the kind of record an international regulator can use to assess whether a quality system functions under real manufacturing conditions. That gap is not a capability deficit or a resource problem. It is the natural result of building a quality system before you have been tested on it. The difficulty is that the test here is an international inspection, not an internal audit.

For any Nigerian manufacturer that eventually seeks WHO prequalification or FDA approval to export to regulated markets, the GMP requirements are substantively equivalent regardless of the facility's location. WHO-PQ assessors evaluate CAPA adequacy, data integrity practices, laboratory controls, environmental monitoring design, and documentation sufficiency against ICH Q10 pharmaceutical quality system standards and WHO GMP guidelines, the same requirements applied to manufacturers in India, Germany, or the United States. Geographic proximity to the NAFDAC approval decision offers no advantage when a WHO inspector arrives with an assessment protocol built for an international standard.

The inspection patterns that emerge at newly-established manufacturers are consistent across geographies and product types. CAPA systems that have formal procedures but no demonstrated effectiveness history. Deviation investigations that close quickly because operations are new and the team has not yet built the organizational habit of asking whether similar incidents occurred elsewhere in the same facility. Data integrity practices that were not designed with audit trail requirements in mind and cannot easily be retrofitted after a production system is running. Environmental monitoring programs for sterile operations that meet the minimum specification on paper but were not calibrated against the actual contamination history being generated during real production runs.

None of these failure modes are unique to first-time manufacturers in Nigeria. They appear on 483 observations and warning letters at facilities in India, China, Latin America, and the United States. The distinction is timing. An experienced site encountering these findings at an inspection has typically seen variants of them before and has established remediation pathways. A first-time manufacturer encountering the same findings at its inaugural international inspection faces the remediation learning curve simultaneously with the credibility evaluation. That combination is where inspection outcomes tend to turn serious.

For quality consultants and procurement teams sourcing from Nigeria's expanding manufacturing base, the inspection history question now belongs alongside the NAFDAC approval status in any supplier qualification review. A facility cleared for domestic distribution has passed a different assessment than a facility qualified for WHO-PQ-eligible supply chains. As these manufacturers grow into export ambitions, their quality system records will follow them into due diligence processes that regulated-market buyers run on every supplier in their chain. The first time a Nigerian manufacturer's inspection record surfaces in a supplier qualification audit may not be the best moment to discover that the quality system was built for local approval rather than international scrutiny.

Swiss Pharma and Afrimedical demonstrate what building toward international standard looks like from the outset. Both WHO-PQ achievements required sustained investment in the quality infrastructure that inspectors evaluate, not just in the manufacturing infrastructure that produces product. The 5+5 Policy created the conditions for both milestones. The milestones themselves reflect decisions those manufacturers made about what quality systems they wanted to build, not just what facilities.

For quality leaders standing up operations inside Nigeria's 5+5 expansion, or for buyers qualifying manufacturers from this growing supplier base, the operational question is whether the quality system being built would survive the assessment that will eventually come for it. NAFDAC's approval confirms the facility exists. An inspection determines whether what operates inside it is defensible.

Get your Inspection Risk Scan to understand where your quality system exposure sits before an international assessment finds it first.